Model Medicines

Model Medicines is an AI-first biotechnology company engineering first-in-class small molecules that target the biological linchpins underlying disease.

[Model Medicines @modelmedicines]

An antiviral target the field once thought impossible now has the data to prove it's highly conserved. @modelmedicines has established the RdRp Thumb-1 pocket as a conserved, druggable target for broad-spectrum antiviral development.

“This is a highly innovative and mechanistically compelling abstract with strong novelty and potential significance for antiviral drug development. Demonstrates conservation of an allosteric site across viral families, directly contradicting established belief that non-nucleoside antivirals cannot achieve broad-spectrum activity. This is a fundamental shift in antiviral drug development strategy.” - IDWeek 2026 expert peer reviewer

Model Medicines has now presented the discovery of the RdRp Thumb-1 site at
1. IDWeek 2025 (@IDWeekmtg)
2. AASLD 2025 (@AASLDtweets)
3. HepDART 2025 (@IHE_Conferences)
4. CROI 2026 (@IAS_USA)
5. ESCMID2026 (@ESCMID)
6. SERVC 2026 (@EmoryUniversity, @UNC, and @UF)
7. EASL 2026 (@EASLnews)
8. ASV 2026 (@AmerSocVirol)

The preprint, “The RdRp Thumb-1 Pocket is a Conserved Target for Broad-Spectrum Antiviral Development,” is now available on bioRxiv - https://t.co/rtgbUwhWcl.

We’re proud to continue collaborating with Davey Smith, MD, MAS, FACP, FIDSA (@DaveySmithMD, @UCSDHealth) and Philippe Gallay, PhD (@scrippsresearch)

The Full List of Authors:
Virgil Woods
Tyler Umansky
Sean Russell
Philippe Gallay, Ph.D.
@DaveySmithMD
@DJHadersPhD

Read the full press release here: https://t.co/0kBZcvubLh

[FierceBiotech @FierceBiotech]

Why Model Medicines needs to ‘discover new colors’ in its AI drug discovery quest https://t.co/RF83qVuoZi

[Model Medicines @modelmedicines]

@modelmedicines to Present Evidence of the First Universal Direct-Acting Antiviral for Chronic Hepatitis at CROI 2026

CROI has long been the platform where industry titans like @GileadSciences, @Merck, and @ViiVHC unveil the next generation of standard-of-care. From the pivotal presentations of @VEKLURY(remdesivir) to the evolution of the capsid inhibitor class, this conference defines the frontier of virology.

At CROI 2026, Model Medicines is proud to present MDL-001: a first-in-class, universal oral DAA for Chronic Hepatitis, addressing a critical gap for the 300 million-plus patients.

The Strategic Differentiator:
- Universal Potency: While traditional DAAs are often virus-specific, MDL-001 is the first oral small molecule to show direct-acting activity across HCV, HBV, and HDV simultaneously.
- Solving the Reactivation Paradox: Current HCV DAAs carry an FDA black box warning because clearing HCV can trigger fatal HBV reactivation. MDL-001’s pan-hepatic mechanism suppresses both, potentially eliminating this risk.
- Targeting the "Biological Choke Point": MDL-001 targets the Thumb-1 allosteric domain, a conserved vulnerability shared across viral families.

If you're attending CROI, join @DJHadersPhD
- Session: “Beyond the C: Hepatitis D, B, and E”
- Poster: #589
- Date: Feb 23, 2026 | 2:30 PM MT

#CROI2026 #BiotechInvestment #DrugDiscovery #Hepatitis
Inspired by the work at: @HepBFoundation, @GlobalHep , The Task Force for Global Health,
CGHE Dir. Dr. John Ward, Hepatitis Foundation International,@HIVHep, @gatesfoundation, @BlumbergInstit1, @liverUSA, @Hep_Alliance, @GlobalHepSummit, @CDAFound, @GlobalFund, @CHAI_health, @AASLDFoundation, @AASLDtweets, @HepatitisCTrust, and the UN Group of Friends to Eliminate Hepatitis.

Committed to the @UN @SustDev Sustainable Development Goal (SDG) 3, specifically Target 3.3, which aims to combat and eliminate viral hepatitis by 2030.

The 2026 Conference on Retroviruses and Opportunistic Infections in partnership with the @IAS_USA

[Model Medicines @modelmedicines]

Model Medicines is heading to #JPM26 Healthcare next week with two lead assets / two first-in-category programs.

MDL-001 - A first-in-category, direct-acting pan-antiviral (DAA) targeting a novel, conserved viral polymerase site. Preclinical data demonstrate equivalency or superiority to current standards, including remdesivir, nirmatrelvir, and sofosbuvir, with the potential to redefine how we treat both known and emerging viral threats.

MDL-4102 - A first-in-category, highly potent and selective oncology asset, discovered through ultra-large-scale AI screening, engineered to overcome historical selectivity and toxicity limitations in its class.

Our GALILEO™ platform - In 2025, we executed the largest ML-driven virtual screen to date (325B molecules in a 24-hour period) and are on track to reach the first trillion-molecule screen in early 2026. Throughput at this scale is how we unlock true novelty, selectivity, and clinical-grade candidates.

We’ll be at JPM connecting with partners, investors, and collaborators who believe the next generation of medicines will be built at the intersection of biology, chemistry, and extreme computational scale.

If you’re attending, connect with @DJHadersPhD

[Model Medicines @modelmedicines]

8/ IND-enabling studies are underway with IND submission targeted for mid-2026 and clinical trials late 2026.

Full preclinical data package: https://t.co/783PuYhyKf

[Model Medicines @modelmedicines]

🚨Major breakthrough in antiviral drug development 🚨

1/ We're announcing groundbreaking preclinical data for MDL-001. A direct-acting, pan-antiviral demonstrating clinical equivalence across six viral families. Showing superiority or equivalence to 3 current standards of care.

[Model Medicines @modelmedicines]

7/ Commercial opportunity: The three comparator drugs generated over $9B in combined revenues in 2024 (nirmatrelvir: $5.7B, remdesivir: $1.8B, sofosbuvir: $1.6B).

MDL-001 could exceed $10-15B annually across the current markets for: RSV, COVID-19, Influenza, HCV, HBV, and HDV.

[Model Medicines @modelmedicines]

🌐 MDL-001 also aligns with @NIAIDNews
Target Product Profile (TPP) for pandemic-ready antivirals. https://t.co/ggoilEeZyB

[Model Medicines @modelmedicines]

💊 Model Medicines Presenting MDL-001 at @IDWeekmtg 2025
🚀 On the Path to the Clinic

We've been selected for an oral presentation at IDWeek 2025, where we will share the complete preclinical Proof-of-Concept data package for MDL-001, our oral, broad-spectrum antiviral. 🧵

[Model Medicines @modelmedicines]

MDL-001: An Oral, Safe, and Well-Tolerated Broad-Spectrum Inhibitor of Viral Polymerases.

Full preprint here: https://t.co/olupsJANfg

[Model Medicines @modelmedicines]

Thanks to:
Adolfo García-Sastre, PhD (@MountSinaiNYC, @IcahnMountSinai)
Kris White, PhD (@MountSinaiNYC, @IcahnMountSinai)
Davey Smith, MD (@DaveySmithMD, @UCSDHealth)
Philippe Gallay, PhD (@scrippsresearch)

Also
@CoRESinai
@VivianaSimonLab

[Model Medicines @modelmedicines]

Earlier, we released preclinical results demonstrating in vivo efficacy for MDL-001 against SARS-CoV-2 with the @IcahnMountSinai and @UCSDHealth

At @IDWeekmtg 2025, we plan to present two additional in-vivo efficacy studies and a range of in-vitro studies from @scrippsresearch

[Model Medicines @modelmedicines]

Full announcement: https://t.co/zg6bQBwSPV